High-risk human papillomavirus testing in women with ASCUS cytology: results from The ATHENA HPV study

This study evaluated the clinical performance of cobas 4800 HPV Test (Roche Molecular Systems, Pleasanton, CA, USA) for high-risk human papillomavirus (HR-HPV) testing with individual HPV-16/HPV-18 genotyping in women 21 years or older atypical squamous cells undetermined significance (ASCUS). Women (N = 47,208) were recruited United States during routine screening, and liquid-based cytology performed. The ASCUS prevalence was 4.1% (1,923/47,208), 1,578 underwent colposcopy valid results. demonstrated comparable to Hybrid Capture 2 test (QIAGEN, Gaithersburg, MD, detection cervical intraepithelial neoplasia (CIN) grade worse 3 worse. HPV-16/HPV-18+ had a greater absolute risk CIN compared pooled HR-HPV+ HR-HPV- (24.4%, 14.0%, 0.8%, respectively).The is clinically validated triage. can identify at highest high-grade disease, this additional stratification may be used formulating patient management decisions.